Ipilimumab & Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InterveNtion or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or MEtastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- Acronyms INTENSE
- 21 Nov 2018 Planned End Date changed from 1 Feb 2021 to 31 Aug 2020.
- 21 Nov 2018 Planned primary completion date changed from 1 Feb 2021 to 31 Aug 2020.
- 21 Nov 2018 Status changed from not yet recruiting to recruiting.